Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses (Tables)

v3.10.0.1
Accrued Expenses (Tables)
 9 Months Ended
Sep. 30, 2018
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued expenses consisted of the following:

 

    September 30, 2018     December 31, 2017  
             
Accrued clinical operations and trials costs   $ 4,223,787     $ 2,003,799  
Accrued product development costs     1,333,392       1,255,439  
Accrued compensation     1,504,736       1,335,672  
Accrued other     323,681       146,609  
Total   $ 7,385,596     $ 4,741,519